NASDAQ:BNTX BioNTech (BNTX) Stock Price, News & Analysis → Grab Your Free Bitcoin Today! (From Crypto Swap Profits) (Ad) Free BNTX Stock Alerts $92.25 -0.72 (-0.77%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$92.20▼$93.8450-Day Range$88.96▼$100.2952-Week Range$85.21▼$131.52Volume433,116 shsAverage Volume728,796 shsMarket Capitalization$21.93 billionP/E Ratio22.39Dividend YieldN/APrice Target$120.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get BioNTech alerts: Email Address BioNTech MarketRank™ Stock AnalysisAnalyst RatingHold2.30 Rating ScoreUpside/Downside30.5% Upside$120.40 Price TargetShort InterestBearish1.30% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.08Based on 14 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.10) to ($1.58) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.37 out of 5 starsMedical Sector517th out of 939 stocksBiological Products, Except Diagnostic Industry89th out of 158 stocks 4.2 Analyst's Opinion Consensus RatingBioNTech has received a consensus rating of Hold. The company's average rating score is 2.30, and is based on 4 buy ratings, 5 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $120.40, BioNTech has a forecasted upside of 30.5% from its current price of $92.25.Amount of Analyst CoverageBioNTech has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted1.30% of the float of BioNTech has been sold short.Short Interest Ratio / Days to CoverBioNTech has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in BioNTech has recently increased by 5.48%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioNTech does not currently pay a dividend.Dividend GrowthBioNTech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BNTX. Previous Next 1.1 News and Social Media Coverage News SentimentBioNTech has a news sentiment score of -0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for BioNTech this week, compared to 8 articles on an average week.Search InterestOnly 35 people have searched for BNTX on MarketBeat in the last 30 days. This is a decrease of -3% compared to the previous 30 days.MarketBeat FollowsOnly 57 people have added BioNTech to their MarketBeat watchlist in the last 30 days. This is a decrease of -34% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioNTech insiders have not sold or bought any company stock.Percentage Held by Insiders19.20% of the stock of BioNTech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 15.52% of the stock of BioNTech is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for BioNTech are expected to decrease in the coming year, from ($1.10) to ($1.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioNTech is 22.39, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 136.21.Price to Earnings Ratio vs. SectorThe P/E ratio of BioNTech is 22.39, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 182.24.Price to Book Value per Share RatioBioNTech has a P/B Ratio of 1.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Prosper Trading AcademyDid you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:Click Here To Get Your Free Copy About BioNTech Stock (NASDAQ:BNTX)BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.Read More BNTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BNTX Stock News HeadlinesMarch 28, 2024 | americanbankingnews.comBioNTech (NASDAQ:BNTX) Price Target Lowered to $101.00 at UBS GroupMarch 26, 2024 | investorplace.com3 Biotech Stocks to Buy for the Next Bull Run: March 2024March 29, 2024 | Crypto 101 Media (Ad)Crypto Market Preps For Trillions Worth of Inflows! Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.March 26, 2024 | finance.yahoo.comThis Vaccine Maker Sits on Cash Almost Equal to Its Market ValueMarch 25, 2024 | markets.businessinsider.comOptimistic Outlook for BioNTech: A Buy Rating Amidst Vaccine Demand and Strong Oncology PipelineMarch 24, 2024 | finance.yahoo.comBioNTech Full Year 2023 Earnings: Misses ExpectationsMarch 23, 2024 | finance.yahoo.comEarnings Miss: BioNTech SE Missed EPS By 14% And Analysts Are Revising Their ForecastsMarch 23, 2024 | americanbankingnews.comBioNTech (NASDAQ:BNTX) PT Lowered to $90.00 at JPMorgan Chase & Co.March 29, 2024 | Crypto 101 Media (Ad)Crypto Market Preps For Trillions Worth of Inflows! Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.March 23, 2024 | americanbankingnews.comCanaccord Genuity Group Reiterates Buy Rating for BioNTech (NASDAQ:BNTX)March 22, 2024 | americanbankingnews.comBioNTech (NASDAQ:BNTX) Price Target Cut to $123.00 by Analysts at BMO Capital MarketsMarch 22, 2024 | americanbankingnews.comBioNTech SE (NASDAQ:BNTX) Receives Consensus Rating of "Hold" from AnalystsMarch 22, 2024 | msn.comBioNTech Tumbles as Q4 Profit, Sales Trail Estimates on Falling COVID-19 Vaccine DemandMarch 21, 2024 | msn.comWhy Is BioNTech Stock Trading Lower On Wednesday?March 21, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Edwards Lifesciences (EW) and Innovent Biologics (OtherIVBXF)March 21, 2024 | markets.businessinsider.comHold Rating for BioNTech: Navigating Vaccine Revenue Decline and Prospective Oncology PipelineMarch 21, 2024 | finance.yahoo.comBioNTech SE (NASDAQ:BNTX) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | markets.businessinsider.comMaintaining Hold on BioNTech: A Balancing Act Between Near-Term Challenges and Long-Term Oncology InvestmentMarch 20, 2024 | msn.comBioNTech slides as earnings plunge amid cancer drug shiftMarch 20, 2024 | seekingalpha.comPfizer partner BioNTech ekes out Q4 profit despite 65% revenue dropMarch 20, 2024 | finance.yahoo.comBioNTech Touts Its Oncology Shift After Reporting Disappointing Fourth Quarter FinancialsMarch 20, 2024 | rttnews.comBioNTech Q4 Net Profit Plummets March 20, 2024 | seekingalpha.comBioNTech's Brew: Mixing COVID Legacy With Oncology AmbitionsMarch 20, 2024 | investorplace.comBNTX Stock Earnings: BioNTech Misses EPS, Misses Revenue for Q4 2023March 20, 2024 | barrons.comBioNTech Earnings Fall Short of Estimates. The Stock Is Down.March 20, 2024 | finanznachrichten.deBioNTech SE: BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate UpdateMarch 20, 2024 | reuters.comAfter earnings plunge, BioNTech pins hopes on cancer drug launchesSee More Headlines Receive BNTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioNTech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/06/2023Today3/29/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:BNTX CUSIPN/A CIK1776985 Webwww.biontech.de Phone49-61-31908-40Fax49-6131-908-4390Employees6,133Year Founded2008Price Target and Rating Average Stock Price Target$120.40 High Stock Price Target$171.00 Low Stock Price Target$90.00 Potential Upside/Downside+30.5%Consensus RatingHold Rating Score (0-4)2.30 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$4.12 Trailing P/E Ratio22.39 Forward P/E RatioN/A P/E GrowthN/ANet Income$1.01 billion Net Margins24.26% Pretax Margin31.06% Return on Equity4.60% Return on Assets4.12% Debt Debt-to-Equity Ratio0.01 Current Ratio9.43 Quick Ratio9.26 Sales & Book Value Annual Sales$4.13 billion Price / Sales5.31 Cash Flow$5.10 per share Price / Cash Flow18.09 Book Value$92.17 per share Price / Book1.00Miscellaneous Outstanding Shares237,730,000Free Float192,083,000Market Cap$21.93 billion OptionableOptionable Beta0.23 Social Links Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Ugur Sahin M.D. (Age 59)Co-Founder, CEO & Chair of the Management Board Comp: $1.25MDr. Ozlem Tureci M.D. (Age 57)Co-Founder, Chief Medical Officer & Member of Management Board Comp: $822.13kMr. Jens H. Holstein (Age 61)CFO & Member of Management Board Comp: $1.44MDr. Sierk Poetting Ph.D. (Age 51)MD, COO & Member of Management Board Comp: $844.88kMr. Ryan Richardson (Age 45)Chief Strategy Officer, MD & Member of Management Board Comp: $1.04MMr. Sean Marett (Age 59)Chief Business Officer, Chief Commercial Officer & Member of Management Board Comp: $815.63kDr. James Timothy Patrick Ryan Ph.D. (Age 49)Chief Legal Officer & Member of the Management Board Comp: $610.91kMr. Zach TaylorSenior Vice President of Corporate Development & StrategyDr. Katalin Kariko Ph.D.Senior VP & External Consultant for RNA Protein Replacement TherapiesDr. Oliver Henning Ph.D.Senior Vice President of OperationsMore ExecutivesKey CompetitorsargenxNASDAQ:ARGXNeurocrine BiosciencesNASDAQ:NBIXBiogenNASDAQ:BIIBBio-TechneNASDAQ:TECHRepligenNASDAQ:RGENView All CompetitorsInstitutional OwnershipNewbridge Financial Services Group Inc.Sold 266 shares on 3/28/2024Ownership: 0.000%PNC Financial Services Group Inc.Bought 1,743 shares on 3/22/2024Ownership: 0.001%Goldman Sachs Group Inc.Bought 26,777 shares on 3/1/2024Ownership: 0.077%Investmentaktiengesellschaft Fuer Langfristige Investoren TGVBought 3,000 shares on 3/1/2024Ownership: 0.006%Quintet Private Bank Europe S.A.Sold 440 shares on 2/29/2024Ownership: 0.000%View All Institutional Transactions Should I Buy BioNTech Stock? BNTX Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in BioNTech SE: BioNTech SE is actively developing a range of immunotherapies for cancer and infectious diseases, showing a commitment to addressing critical medical needs. The company has a diverse pipeline of product candidates, including BNT122 in Phase II clinical trial for first-line melanoma and BNT311 in Phase II clinical trial for metastatic non-small cell lung cancer, indicating potential for future revenue growth. Collaborations with established pharmaceutical companies like Genentech, Pfizer, and Sanofi provide BioNTech SE with resources, expertise, and potential market access, enhancing its competitive position. The company's focus on developing prophylactic vaccines for various infectious diseases demonstrates a proactive approach to public health challenges, potentially leading to increased demand and revenue diversification. Recent positive developments and advancements in the company's clinical trials may indicate strong potential for future success, influencing investor confidence and stock price performance. Cons Investors should be bearish about investing in BioNTech SE for these reasons: Biotechnology investments can be high-risk due to the uncertainty of clinical trial outcomes, regulatory approvals, and market acceptance, which may lead to significant financial losses. The competitive landscape in the biotechnology industry is intense, with other companies also developing innovative therapies, posing challenges to BioNTech SE's market share and profitability. Market volatility and macroeconomic factors can impact biotech stocks, including BioNTech SE, leading to fluctuations in stock price and potential investor anxiety. Dependency on successful clinical trial results for product candidates like BNT122 and BNT311 may introduce delays, setbacks, or failures, affecting the company's revenue projections and investor confidence. Investors should carefully consider the current stock price of BioNTech SE in relation to its financial performance, market position, and growth prospects to make informed investment decisions. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, March 27, 2024. Please send any questions or comments about these BioNTech pros and cons to contact@marketbeat.com. BNTX Stock Analysis - Frequently Asked Questions Should I buy or sell BioNTech stock right now? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BNTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BNTX, but not buy additional shares or sell existing shares. View BNTX analyst ratings or view top-rated stocks. What is BioNTech's stock price target for 2024? 10 Wall Street analysts have issued 12-month price targets for BioNTech's shares. Their BNTX share price targets range from $90.00 to $171.00. On average, they predict the company's stock price to reach $120.40 in the next twelve months. This suggests a possible upside of 30.5% from the stock's current price. View analysts price targets for BNTX or view top-rated stocks among Wall Street analysts. How have BNTX shares performed in 2024? BioNTech's stock was trading at $105.54 at the beginning of 2024. Since then, BNTX stock has decreased by 12.6% and is now trading at $92.25. View the best growth stocks for 2024 here. Are investors shorting BioNTech? BioNTech saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 3,080,000 shares, an increase of 5.5% from the February 29th total of 2,920,000 shares. Based on an average daily volume of 689,800 shares, the days-to-cover ratio is currently 4.5 days. Approximately 1.3% of the company's shares are sold short. View BioNTech's Short Interest. When is BioNTech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our BNTX earnings forecast. How were BioNTech's earnings last quarter? BioNTech SE (NASDAQ:BNTX) announced its quarterly earnings results on Monday, November, 6th. The company reported $0.67 earnings per share for the quarter, beating analysts' consensus estimates of ($0.59) by $1.26. The firm earned $895.30 million during the quarter, compared to analyst estimates of $850.50 million. BioNTech had a net margin of 24.26% and a trailing twelve-month return on equity of 4.60%. The business's quarterly revenue was down 74.1% on a year-over-year basis. During the same quarter last year, the firm earned $7.04 earnings per share. What ETFs hold BioNTech's stock? ETFs with the largest weight of BioNTech (NASDAQ:BNTX) stock in their portfolio include Morningstar US Small Growth (MSGR), Amplify Treatments, Testing and Advancements ETF (GERM), Global X Genomics & Biotechnology ETF (GNOM), iShares Genomics Immunology and Healthcare ETF (IDNA), First Trust NYSE Arca Biotechnology Index Fund (FBT), VanEck Biotech ETF (BBH), Franklin Genomic Advancements ETF (HELX) and iShares Biotechnology ETF (IBB). What guidance has BioNTech issued on next quarter's earnings? BioNTech issued an update on its FY 2024 earnings guidance on Tuesday, January, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $3.2 billion-$3.2 billion, compared to the consensus revenue estimate of $4.2 billion. What is Ugur Sahin's approval rating as BioNTech's CEO? 33 employees have rated BioNTech Chief Executive Officer Ugur Sahin on Glassdoor.com. Ugur Sahin has an approval rating of 89% among the company's employees. 81.0% of employees surveyed would recommend working at BioNTech to a friend. What other stocks do shareholders of BioNTech own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioNTech investors own include Moderna (MRNA), Pfizer (PFE), Inovio Pharmaceuticals (INO), Tesla (TSLA), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Zoom Video Communications (ZM) and Advanced Micro Devices (AMD). When did BioNTech IPO? BioNTech (BNTX) raised $251 million in an initial public offering on Thursday, October 10th 2019. The company issued 13,200,000 shares at a price of $18.00-$20.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink served as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers. Who are BioNTech's major shareholders? BioNTech's stock is owned by many different institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (3.66%), Primecap Management Co. CA (2.00%), Harding Loevner LP (1.66%), Flossbach Von Storch AG (1.49%), Capital World Investors (0.39%) and Voloridge Investment Management LLC (0.25%). How do I buy shares of BioNTech? Shares of BNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does BioNTech have any subsidiaries? The following companies are subsidiares of BioNTech: Apta IT, BioNTech Austria Beteiligungen GmbH, BioNTech Business Services, BioNTech Cell & Gene Therapies, BioNTech Diagnostics, BioNTech Innovative Manufacturing Services, BioNTech Protein Therapeutics, BioNTech RNA Pharmaceuticals, BioNTech Real Estate GmbH & Co. KG, BioNTech Real Estate Verwaltungs, BioNTech Research and Development, BioNTech Small Molecules, BioNTech USA Holding, JPT, TheraCode JPT, and reBOOST Management.Read More This page (NASDAQ:BNTX) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeYour Money is Not SafeAmerican AlternativeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaThe ONE AI Sock to own now. (It’s not Nvidia.)Weiss Ratings“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioNTech SE Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.